Altimmune Obesity Drug Provides Class-Leading Lean Mass Preservation

Clinical-stage biopharmaceutical company, Altimmune, Inc (Nasdaq: ALT) topped the PRISM Global Health Index on Monday morning after the company presented data from a 48-week Phase 2 clinical trial of pemvidutide, the company’s GLP-1/glucagon dual receptor agonist candidate, in obesity. Altimmune’s share price rose by 17.69% in morning trading following the news.

Altimmune presented data that included the results of a recently completed body composition analysis, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. Full analysis of the body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat. The study enrolled 391 subjects with obesity, randomized to receive pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise.

Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “The preservation of lean mass observed in this trial was better than reported historically with diet and exercise programs and greater than what has been publicly reported with other incretin weight loss drugs, where lean mass has accounted for as much as 40% of total weight loss. Preservation of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical function. We believe that the level of muscle preservation observed in the Phase 2 trial further adds to the differentiation of pemvidutide in the treatment of obesity.”

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Share This Article

 

About the Author

Altimmune Obesity Drug Provides Class-Leading Lean Mass Preservation

Catie Corcoran

Biotech Editor